# Comparison of Protein Carbonyl (PCO), Paraoxonase-1 (PON1) and C-Reactive Protein (CRP) as Diagnostic and Prognostic Markers of Septic Inflammation in Dogs

Beatrice Ruggerone, Donatella Scavone, Roberta Troia, Massimo Giunti, Francesco Dondi, Saverio Paltrinieri

► To cite this version:

Beatrice Ruggerone, Donatella Scavone, Roberta Troia, Massimo Giunti, Francesco Dondi, et al. Comparison of Protein Carbonyl (PCO), Paraoxonase-1 (PON1) and C-Reactive Protein (CRP) as Diagnostic and Prognostic Markers of Septic Inflammation in Dogs. Veterinary Sciences, 2021, 8, 10.3390/vetsci8060093. [hal-05483159]

HAL Id: hal-05483159

https://hal.science/hal-05483159v1

Submitted on 29 Jan 2026

HAL is a multi-disciplinary open access
archive for the deposit and dissemination of sci-
entific research documents, whether they are pub-
lished or not. The documents may come from
teaching and research institutions in France or
abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire HAL, est
destinée au dépôt et à la diffusion de documents
scientifiques de niveau recherche, publiés ou non,
émanant des établissements d'enseignement et de
recherche français ou étrangers, des laboratoires
publics ou privés.

<figure><img src="image_1.png" /></figure>

Distributed under a Creative Commons CC BY 4.0 - Attribution - International License
<figure><img src="image_2.png" /></figure>

Article

Comparison of Protein Carbonyl (PCO), Paraoxonase-1 (PON1) and C-Reactive Protein (CRP) as Diagnostic and Prognostic Markers of Septic Inflammation in Dogs

Beatrice Ruggerone <fnref n="1" />,<fnref n="2" />,<fnref n="3" /> ID, Donatella Scavone <fnref n="1" />,<fnref n="2" /> ID, Roberta Troia <fnref n="4" />, Massimo Giunti <fnref n="4" />,* ID, Francesco Dondi <fnref n="4" /> ID
and Saverio Paltrinieri <fnref n="1" />,<fnref n="2" /> ID

<figure><img src="image_3.png" /></figure>

check for
updates

**Citation:** Ruggerone, B.; Scavone, D.; Troia, R.; Giunti, M.; Dondi, F.; Paltrinieri, S. Comparison of Protein Carbonyl (PCO), Paraoxonase-1 (PON1) and C-Reactive Protein (CRP) as Diagnostic and Prognostic Markers of Septic Inflammation in Dogs. *Vet. Sci.* **2021**, *8*, 93. https://doi.org/10.3390/vetsci8060093

Received: 2 May 2021

Accepted: 26 May 2021

Published: 29 May 2021

**Publisher's Note:** MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

<figure><img src="image_4.png" /></figure>

**Copyright:** © 2021 by the authors.
Licensee MDPI, Basel, Switzerland.
This article is an open access article
distributed under the terms and
conditions of the Creative Commons
Attribution (CC BY) license (https://
creativecommons.org/licenses/by/
4.0/).

**Abstract:** Reliable diagnostic and prognostic markers of sepsis are lacking, but essential in veterinary medicine. We aimed to assess the accuracy of C-Reactive Protein (CRP), protein carbonyls (PCO) and paraoxonase-1 (PON1) in differentiating dogs with sepsis from those with sterile inflammation and healthy ones, and predict the outcome in septic dogs. These analytes were retrospectively evaluated at admission in 92 dogs classified into healthy, septic and polytraumatized. Groups were compared using the Kruskal–Wallis test, followed by a Mann–Whitney *U* test to assess differences between survivors and non-survivors. Correlation between analytes was assessed using the Spearman’s test, and their discriminating power was assessed through a Receiver Operating Characteristic (ROC) curve. PON1 and CRP were, respectively, significantly lower and higher in dogs with sepsis compared with polytraumatized and clinically healthy dogs (*p* < 0.001 for both the analytes), and also in dogs with trauma compared with healthy dogs (*p* = 0.011 and *p* = 0.017, respectively). PCO were significantly increased in septic (*p* < 0.001) and polytraumatized (*p* < 0.005) as compared with healthy dogs. PON1 and CRP were, respectively, significantly lower and higher in dogs that died compared with survivors (*p* < 0.001 for both analytes). Ultimately, evaluation of CRP and PON1 at admission seems a reliable support to diagnose sepsis and predict outcomes.

**Keywords:** acute phase protein; canine; inflammation; oxidative stress; prognosis; sepsis

**1. Introduction**

The management of dogs with systemic and severe clinical signs associated with sepsis often represents a challenge in clinical practice: veterinarians should provide reliable information to owners both about the prognosis and the treatment cost estimation. The decision to hospitalize or to euthanize a pet is often strictly correlated to these features. Moreover, the early exclusion of septic processes is pivotal to select those cases on which antibiotic therapy is not necessary or even harmful for the patient. For example, canine pancreatitis is frequently associated with a systemic inflammatory response syndrome (SIRS) and its possible consequences (e.g., acute kidney injury, multi organ dysfunction, disseminated intravascular coagulation) without being related to a septic etiology [1–4]. In these cases, the administration of antibiotics could modify the gut microbiota, causing additional disabling symptoms (e.g., diarrhea) and weakening the immune system [5–8]. Moreover, the abuse of antibiotics in patients without septic conditions would amplify the worldwide problem of drug resistance.

Unfortunately, reliable diagnostic and prognostic markers of sepsis are still lacking in veterinary medicine. Little information is available about the potential utility of markers

<footnote n="1">¹ Department of Veterinary Medicine, University of Milan, Via Celoria, 10, 20133 Milano, Italy;
beatrice.ruggerone@gmail.com (B.R.); donatella.scavone@unimi.it (D.S.); saverio.paltrinieri@unimi.it (S.P.)</footnote>

<footnote n="2">² Veterinary Teaching Hospital, University of Milan, Via dell'Università 6, 26900 Lodi, Italy</footnote>

<footnote n="3">³ Ospedale Veterinario I Portoni Rossi, Via Roma, 57/a, Zola Predosa, 40069 Bologna, Italy</footnote>

<footnote n="4">⁴ Department of Veterinary Medical Science, Alma Mater Studiorum, University of Bologna,
Ozzano dell'Emila (BO), 40064 Bologna, Italy; roberta.troia2@unibo.it (R.T.); f.dondi@unibo.it (F.D.)</footnote>

<footnote>* Correspondence: massimo.giunti@unibo.it</footnote>
commonly used in human medicine to diagnose or stage sepsis. Several markers have been
tested in recent years, including methemoglobin fractions, adiponectin, apolipoprotein
A1 [9–11] and especially procalcitonin. The latter has an acknowledged relevant role
in diagnosing sepsis in people, while some limitations were reported in dogs [12,13].
Specifically, some concern was initially raised about the analytical accuracy of commercially
available reagents in measuring canine procalcitonin [14], but a recent report demonstrated
its increase in serum of dogs with experimentally induced endotoxemia [15]. However,
clinical studies involving septic patients demonstrated a substantial overlap with results
recorded in non-septic conditions [16] and its usefulness in practice seems to be associated
with its ability to predict organ dysfunction, especially through serial measurements over
the course of the disease [17]. Before these recent studies, C reactive protein (CRP) has been
widely used as a marker of sepsis in dogs [18–20] and remains to date the most used in
routine practice. However, CRP may have a low specificity in diagnosing sepsis, because its
serum concentration may increase in several non-septic inflammatory or non-inflammatory
conditions [21–26].

Inflammation is characterized by a sequela of events, mostly associated with the
activation of phagocytes, which generates reactive oxygen species (ROS) and other ox-
idants. This induces an imbalance between oxidants and antioxidant defenses known
as oxidative stress, due to the sustained production of oxidative compounds and to the
consumption of antioxidants, whose serum concentration decreases [27]. During sepsis, a
hyperinflammatory state develops, and the resulting oxidative stress is higher than in non-
septic inflammation [28–32]. Paraoxonase-1 (PON1) is a serum enzyme with antioxidant
properties. During inflammation, serum PON1 activity decreases, due to both changes
in composition and structure of circulating PON1 and decreased hepatic synthesis [33].
Decreases in serum PON1 activity have already been demonstrated in some, but not all,
dogs with inflammation [34,35], likely because oxidation is particularly intense only in
some types of inflammation or when inflammation is more severe. As a support to this
latter hypothesis, several studies postulated that serum PON1 may be a marker of severity
of inflammation [9,36–38].

The ROS produced during oxidative stress lead to protein oxidation, and in partic-
ular, to the oxidation of protein side chains, with the subsequent generation of protein
carbonyl (PCO) groups (aldehydes and ketones) [39]. In people, protein carbonylation is
the most widely used biomarker for oxidative damage to proteins, since it reflects cellular
damage induced by multiple forms of ROS [40]; it has been demonstrated that the con-
centration of plasma protein carbonyls is significantly higher in septic patients compared
with controls [41]. In veterinary medicine, few studies have been developed about protein
carbonylation. Validation studies on commercially available ELISA kits are lacking, except
for a recent study that demonstrated that antibody-based techniques may reliably detect
PCO in canine serum and that PCO values seem to be inversely proportional to PON1
levels in dogs with inflammatory diseases [42]. Vannucchi et al. [43] used PCO along with
other markers of oxidation to evaluate the presence and magnitude of oxidative stress
associated with pregnancy in healthy dogs, but no significant changes in the concentra-
tion of PCO were found, and the used method was not validated in dogs. The study
of Escobar et al. [44] assessed plasma PCO both in horses and in dogs with Leishmania
without evidence of a significant difference between sick animals and the control group.
On the other hand, Zini et al. [45] found higher levels of carbonyls in the erythrocytes of
diabetic cats, with a significant decrease after treatment.

For the aforementioned reasons, we hypothesized that dogs with sepsis would exhibit
higher CRP and PCO concentration and lower PON1 activity, due to severe inflammation
and oxidative stress, compared with dogs with non-septic inflammation, and that these
differences could be helpful from a diagnostic, and possibly prognostic, point of view.
The aims of this study were: (1) to compare which analyte, among CRP, PCO and PON1,
better differentiates dogs with sepsis from those with polytrauma or from healthy dogs;
(2) to preliminarily investigate the possible role of CRP, PCO or PON1 in predicting the
prognosis of septic dogs, by assessing if results obtained at admission for each analyte may
be associated with a negative clinical outcome.

**2. Materials and Methods**

**2.1. Caseload**

This retrospective study was done on 92 serum samples collected from privately
owned dogs (37 males, 10 castrated males, 29 females and 16 neutered females) that
underwent clinical examination at the University of Bologna and Milan. Samples were
stored at the same Institutions at -80 °C for a maximum of 12 months. The median
age of the dogs included in the study was 36 months (age range: 1 month-15 years).
Thirty-six dogs were mongrels, whereas the other dogs were: German Shepherds (n = 8),
Golden Retrievers (n = 4), Cavalier King Charles Spaniels, Labrador Retrievers, American
Staffordshire Terriers, Italian Bloodhounds (n = 3 for each breed), Pugs, English Bulldogs,
Miniature Poodles, Doberman Pinschers, Maremmano-Abruzzese Sheepdogs, Jack Russell
Terriers, Rottweilers (n = 2 for each breed), Maltese, Leonberger, Yorkshire Terrier, Bernese
Mountain Dog, English Setter, Dachshund, Shetland Sheepdog, Airedale Terrier, Australian
Shepherd, Great Dane, Shih Tzu, Cocker Spaniel, Chihuahua, Weimaraner, Italian Pointer,
Dogo Argentino, Saluki, Rhodesian Ridgeback, Spanish Greyhound (n = 1 for each breed).
Dogs were divided into the following three groups:

- Group A, clinically healthy: 35 dogs (12 males, 7 castrated males, 10 females, 6 neutered females; median age 24 months, age range: 6 months-13 years) that were considered healthy on the basis of normal physical examination, history and blood test results;

- Group B, septic: 34 dogs (12 males, 2 castrated males, 12 females, 8 neutered females; median age 60 months; age range: 1 month-15 years) that were considered septic as a result of the presence of symptoms such as abnormal mentation, fever or hypothermia, tachycardia, tachypnoea and of appropriate tests on the basis of the suspected diagnosis (e.g., inflammatory leukogram, cytology consistent with presence of intracellular bacteria, abdomen ultrasound examination, thorax X-rays, positive blood culture) [46];

- Group C, non-septic inflammation: 23 dogs (13 males, 1 castrated male, 7 females, 2 neutered females; median age 24 months; age range: 3 months-15 years) polytraumatized after motor vehicle accidents (n = 15) or falls (n = 3) or blunt trauma of unknown origin (n = 5): in these dogs, sepsis was excluded based on history and collateral tests reported above.

Serum samples collected within two hours since first presentation and before starting
any treatment or just after the administration of treatment were included in this study.
Then, all the dogs from Groups B and C received appropriate treatments according to the
diagnosis. For each sick patient, clinical data and outcome were recorded.

All the samples were collected from client-owned dogs for diagnostic purposes or
during routine examinations; an informed consent about the use of residual amounts of
samples for research purposes was signed by the owners. Therefore, according to the
regulations of our Institution, it was not necessary to require a formal authorization to
the Institutional animal care committee (Decision of the institutional committee no. 2/16
dated 15/02/16).

**2.2. Measurement of PCO, PON1 and CRP**

The serum concentration of PCO was measured in 41 samples (15 from Group A, 14 from Group B and 12 from Group C) using a commercially available ELISA kit (Enzo Life science, 3V Chimica, Roma, Italy) following manufacturer's instructions. The plate was read with an automated plate reader (Dasit multiscan, Dasit, Cornaredo, Milan, Italy) using a wavelength of 450 nm. A regression standard curve was then designed by plotting the lot specific nmoL/mg protein carbonyl concentration of the standards, against their absorbances. The concentration of PCO in each sample was then calculated by interpolating the absorbance of each sample with the standard curve.
The serum activity of PON1 was measured in all the samples included in this study using an automated chemistry analyzer (Cobas Mira, Roche Diagnostics, Basel, Switzerland), as previously described [34,47]. Serum PON1 activity was measured spectrophotometrically using the enzymatic method proposed by [33]: briefly, 6 µL of samples were incubated at 37 °C with 89 µL of distilled water and 100 µL of reaction buffer (glycine buffer 0.05 mM, pH 10.5 containing 1 mM of paraoxon-ethyl, purity > 90%, and 1 mM of CaCl₂). The rate of hydrolysis of paraoxon to p-nitrophenol was measured by monitoring the increase in absorbance at 405 nm using a molar extinction coefficient of 18.050 L mol⁻¹ cm⁻¹. The unit of PON1 activity expressed as U/mL is defined as 1 nmol of p-nitrophenol formed per minute under the assay conditions.

The serum concentration of CRP was measured in 87 serum samples (35 from Group A, 32 from Group B and 20 from Group C) using the automated analyzer BT3500 (Biotecnica Instruments SPA, Roma, Italy) using an immunoturbidimetric method provided by the manufacturer of the analyzer.

## 2.3. Statistical Analysis

Statistical analysis was performed in an Excel spreadsheet using a specific software (Analyse-it, Analyse-it Software Ltd., Leeds, UK). Statistical differences were set for *p* < 0.05.

The mortality rates recorded in the two pathologic groups were compared to each other using a Pearson chi-square test. Results regarding PCO, PON1 and CRP were compared in each group of dogs using the Kruskal–Wallis test, followed by a Mann–Whitney *U* test to assess the differences between single groups. The Mann–Whitney *U* test was used also to compare the results obtained at admission from animals that died with those that survived. These comparisons were performed either on the whole caseload or on sick dogs (Groups B and C), in order to draw information more relevant to the clinical application of the test.

A Spearman's correlation test was used to correlate the results of PCO, PON1 and CRP in the 36 samples on which all the analytes were measured.

In order to assess the discriminating power of the three analytes in detecting dogs with sepsis or with a poor outcome and to establish the optimal diagnostic cut-off, for each numerical value recorded in the study (operating point), we classified as true or false positive the dogs with or without sepsis or the dogs that died or not, that had PCO or CRP values higher and PON1 values lower than each operating point, and as true or false negative the dogs with or without sepsis or the dogs that died or not that had PCO or CRP values lower and PON1 values higher than each operating point. Sensitivity and specificity and the positive likelihood ratio were calculated for each analyte and for each operating point, using standard formulae [48,49], and receiver operating characteristic (ROC) curves were designed by plotting sensitivity versus (1-specificity) [48]. The Youden index (i.e., the operating point that maximizes the difference between true positives and false positives) and the operating points characterized by the highest LR+ and by absolute specificity were then calculated [50]. Additionally, the evaluation of sensitivity and specificity and ROC curve analyses were performed first by also including the control group and then excluding the control group.

# 3. Results

## 3.1. Group Composition

The mortality rate was significantly lower (*p* = 0.027) in the non-septic group (3/23; 13.0%) than in the septic group (14/34; 41.2%). No significant differences were found regarding the age (*p* = 0.150) or the proportion of male or female dogs (*p* = 0.211) among the three groups.

## 3.2. Group Comparison and ROC Curve Analyses for the Diagnosis of Sepsis

A significant difference among groups was found for the serum concentrations of PCO and CRP as well as for PON1 activity (*p* < 0.001 for all the analytes, Table 1, Figure 1).
<table><caption>**Table 1.** Mean ± SD, median (between parenthesis) and min-max range of PCO, CRP and PON1 in dogs with sepsis, trauma and clinically healthy dogs.</caption><thead><tr><th>Dogs</th><th>PON1 (U/mL)</th><th>CRP (mg/L)</th><th>PCO (nmol/mg of Protein)</th></tr></thead><tbody><tr><td>Sepsis</td><td>96.4 ± 44.4 (88.7) *** ††† (‡)</td><td>24.22 ± 12.47 (20.60) *** ††† (‡‡)</td><td>0.40 ± 0.22 (0.31) ***<br>0.22–0.89</td></tr><tr><td>Trauma</td><td>126.6 ± 25.1 (111.5) ***<br>89.6–184.4</td><td>9.46 ± 9.36 (6.17) *<br>0.00–30.60</td><td>0.27 ± 0.08 (0.30) **<br>0.11–0.35</td></tr><tr><td>Clinically healthy</td><td>176.8 ± 24.4 (179.5)<br>126.0–220.6</td><td>2.88 ± 3.76 (1.72)<br>0.00–20.50</td><td>0.20 ± 0.06 (0.21)<br>0.10–0.29</td></tr></tbody></table>

<figure><img src="image_5.png" /><figcaption>**Figure 1.** Serum PON1 activity (A) and concentration of CRP (B) and PCO (C) in clinically healthy dogs, in dogs with sepsis and in those with polytrauma. The boxes indicate the I-III interquartile range (IQR), the horizontal black line indicates the median values, whiskers extend to further observation within quartile I minus 1.5 × IQR or to further observation within quartile III plus 1.5 × IQR. Black dots indicate the results that are not classified as outliers. White dots indicate near outliers (values exceeding the third quartile ± (1.5 × IQR)) and grey dots indicate far outliers (values exceeding the third quartile ± (3.0 × IQR)).</figcaption></figure>

In particular, the concentration of PCO was significantly higher in dogs with sepsis and in dogs with trauma than in clinically healthy dogs, but no significant differences were found between dogs with trauma or sepsis. Conversely, the serum concentration of CRP was significantly higher in dogs with sepsis than in dogs with trauma and in clinically healthy dogs; a significant difference was also found between dogs with trauma and clinically healthy dogs. Similarly, PON1 activity was significantly lower in dogs with sepsis than in dogs with trauma and in clinically healthy dogs, and a significant difference was found also between dogs with trauma and clinically healthy dogs. The same differences were found when only results from dogs with sepsis or trauma were compared to each other, although the level of significance was lower than in the previous comparison for PON1 (*p* < 0.05). On the whole caseload, PON1 was negatively correlated either with PCO (*p* < 0.001, *r* = −0.594) or with CRP (*p* < 0.001, *r* = −0.510) while PCO and CRP were positively correlated to each other (*p* = 0.007, *r* = 0.440) (Figure 2).

The ROC curve analysis (Figure 3) on the whole caseload demonstrated that all the three analytes had a discriminating power for sepsis (*p* < 0.001 compared with the line of no discrimination) (Table 2). However, the area under the curve (AUC) of PON1 and of CRP were significantly higher than the AUC of PCO, but not significantly different to each other (*p* = 0.990).

Results were substantially similar when the comparison above was repeated excluding clinically healthy dogs, despite all the AUCs were slightly lower than those recorded in the previous comparison and only the ROC curve of PON1 and of CRP, but not that of PCO, had a discriminating power (*p* = 0.001, *p* < 0.001 and *p* = 0.115, respectively). As in the previous comparison, the AUCs of PON1 and CRP and were significantly higher than that of PCO (*p* = 0.034 and *p* = 0.035, respectively), but not significantly different to each other (*p* = 0.928).

<footnote>*** *p* < 0.001 vs. clinically healthy; ** *p* < 0.01 vs. clinically healthy; * *p* < 0.05 vs. clinically healthy; ††† *p* < 0.001 vs. trauma; †††† *p* < 0.001 vs. trauma when only dogs with sepsis and trauma were compared to each other; ‡ *p* < 0.05 vs. trauma when only dogs with sepsis and trauma were compared to each other.</footnote>
<figure><img src="image_6.png" /><figcaption>Figure 2. Correlations between CRP and PCO (A), PON1 and PCO (B), and CRP and PON1 (C).</figcaption></figure>

<figure><img src="image_7.png" /><figcaption>Figure 3. Comparison of ROC curves to support a diagnosis of sepsis designed for PCO (black circles, continuous line), CRP (black triangles, dotted line) and PON1 (black squares, dashed line). The graph on the left (A) includes the results of the three groups of dogs, the graph on the right (B) includes only the results of dogs with sepsis or trauma. The grey line indicates the line of no discrimination. TPF = true positive fraction; FPF = false positive fraction.</figcaption></figure>

<table><caption>**Table 2.** Area under the ROC curves (AUCs), Youden index and operating points characterized by the highest LR+ and by absolute specificity for PON1, CRP and PCO to support a diagnosis of sepsis, calculated either including or excluding clinically healthy dogs from the analysis.</caption><thead><tr><th rowspan="2">Statistical Data</th><th colspan="3">Whole Population</th><th colspan="3">Only Sick Dogs</th></tr><tr><th>PON1 (U/mL)</th><th>CRP (mg/L)</th><th>PCO (nmol/mg of Protein)</th><th>PON1 (U/mL)</th><th>CRP (mg/L)</th><th>PCO (nmol/mg of Protein)</th></tr></thead><tbody><tr><td>AUC (%)</td><td>95 (87–104) *</td><td>95 (91–100) *</td><td>78 (63–93)</td><td>90 (76–104) *</td><td>90 (79–100) *</td><td>63 (41–86)</td></tr><tr><td>Youden index</td><td>98.6 (Y: 0.554)</td><td>5.64 (Y: 0.764)</td><td>0.23 (Y: 0.447)</td><td>91.5 (Y: 0.515)</td><td>15.90 (Y: 0.600)</td><td>0.35 (Y: 0.429)</td></tr><tr><td>Max LR+</td><td>90.9 (LR+ 30.7)</td><td>29.20 (LR+ 20.6)</td><td>0.35 (LR+ 11.6)</td><td>91.1 (LR+ 12.8)</td><td>29.20 (LR+ 7.5)</td><td>0.35 (LR+ 5.1)</td></tr><tr><td>100% Sp</td><td>89.6</td><td>30.60</td><td>0.35</td><td>89.6</td><td>30.30</td><td>0.35</td></tr></tbody></table>

CRP had the highest Youden index, although the cut-off to discriminate septic vs. non-septic dogs was higher when clinically healthy dogs were excluded from the analysis, as expected. The same occurred for PCO and PON1, whose optimal cut-offs were, respectively,

<footnote>* *p* < 0.05 compared with PCO.</footnote>
higher and lower when clinically healthy dogs were excluded from the analysis. Conversely, all the tests had the highest LR⁺ or absolute specificity at similar cut-offs regardless of the presence or absence of clinically healthy dogs, but the LR⁺ was obviously lower when clinically healthy dogs were excluded.

### 3.3. Group Comparison and ROC Curve Analyses Based on the Outcome

Overall, PON1 activity was significantly lower in dogs that died compared with dogs that survived (Table 3, Figure 4).

<table><caption>**Table 3.** Mean ± SD, median (between parenthesis) and min-max range of PCO, CRP and PON1 in dogs that died and dogs that survived, both including and excluding clinically healthy dogs.</caption><thead><tr><th>Dogs</th><th>PON1 (U/mL)</th><th>CRP (mg/L)</th><th>PCO (nmol/mg of Protein)</th></tr></thead><tbody><tr><td>Dead</td><td>79.1 ± 39.0 (67.6) ***<sup>+++</sup><br>14.1–167.4; n = 17</td><td>17.36 ± 11.70 (18.50) *<br>0.00–40.60; n = 16</td><td>0.37 ± 0.22 (0.33)<br>0.15–0.89; n = 9</td></tr><tr><td>Alive (all the groups)</td><td>146.6 ± 40.9 (146.7)<br>28.9–220.6; n = 74</td><td>11.25 ± 13.24 (5.20)<br>0.00–60.70; n = 70</td><td>0.26 ± 0.14 (0.25)<br>0.10–0.86; n = 32</td></tr><tr><td>Alive (only dogs<br>with sepsis or trauma)</td><td>121.1 ± 34.3 (121.7)<br>14.1–106.4; n = 40</td><td>19.07 ± 14.22 (15.35)<br>0.00–60.70; n = 36</td><td>0.32 ± 0.16 (0.28)<br>0.11–0.86; n = 17</td></tr></tbody></table>

<figure><img src="image_8.png" /><figcaption>**Figure 4.** Serum activity of PON1 (A,D) and concentration of CRP (B,E) and PCO (C,F) in dogs that survived or died during the follow up. The analysis was performed either on the whole caseload (upper graphs) or after exclusion of clinically healthy dogs (lower graphs). The boxes indicate the I-III interquartile range (IQR), the horizontal black line indicates the median values, whiskers extend to further observation within quartile I minus 1.5 × IQR or to further observation within quartile III plus 1.5 × IQR. Black dots indicate the results that are not classified as outliers. White dots indicate near outliers (values exceeding the third quartile ± (1.5 × IQR)), and grey dots indicate far outliers (values exceeding the third quartile ± (3.0 × IQR)).</figcaption></figure>

Similarly, the concentration of CRP was significantly different in dogs that died compared with dogs that survived, although with a lower level of significance. Conversely, despite the *P* value being very close to the level of statistical significance (*p* = 0.078), the concentration of PCO was not significantly different in dogs that survived compared with dogs that died. Excluding healthy controls from the analysis, PON1 activity was still significantly lower in dogs that died compared with dogs that survived, and the concentration of PCO was still not significantly different (*p* = 0.726) in dogs that survived compared with dogs that died. On the contrary, the concentration of CRP showed no significant differences (*p* = 0.897) in dogs that died compared with dogs that survived.

<footnote>*** *p* < 0.001 vs. alive (all the groups); * *p* < 0.05 vs. alive (all the groups); **++** *p* < 0.001 vs. alive (only dogs with sepsis or trauma).</footnote>
Based on the ROC curve analysis on the whole caseload (Table 4, Figure 5), only the AUC of PON1 had a discriminating power (*p* < 0.001 compared with the line of no discrimination) and was significantly higher than the AUC of CRP (*p* < 0.001).

<table><caption>**Table 4.** AUCs, Youden index and operating points characterized by the highest LR+ and by absolute specificity for PON1, CRP and PCO to support a poor outcome, calculated either including or excluding clinically healthy dogs from the analysis.</caption><thead><tr><th rowspan="2">Statistical Data</th><th colspan="3">Whole Population</th><th colspan="3">Only Sick Dogs</th></tr><tr><th>PON1 (U/mL)</th><th>CRP (mg/L)</th><th>PCO (nmol/mg of Protein)</th><th>PON1 (U/mL)</th><th>CRP (mg/L)</th><th>PCO (nmol/mg of Protein)</th></tr></thead><tbody><tr><td>AUC (%)</td><td>90 ***<br>(82–99)</td><td>54<br>(38–70)</td><td>70<br>(48–90)</td><td>82 ***<br>(68–96)</td><td>39<br>(22–57)</td><td>54<br>(27–82)</td></tr><tr><td>Youden index</td><td>132.7<br>(Y:0.635)</td><td>13.90<br>(Y:0.454)</td><td>0.35<br>(Y: 0.351)</td><td>90.9<br>(Y: 0.531)</td><td>15.90<br>(Y:0.243)</td><td>0.35<br>(Y:0.268)</td></tr><tr><td>Max LR+</td><td>57.7<br>(LR+ 22.1)</td><td>15.90<br>(LR+ 2.9)</td><td>0.44<br>(LR+ 7.1)</td><td>57.7<br>(LR+ 11.8)</td><td>15.90<br>(LR+ 1.5)</td><td>0.44<br>(LR+ 3.8)</td></tr><tr><td>100% Sp</td><td>28.9</td><td>60.70</td><td>0.86</td><td>28.9</td><td>60.70</td><td>0.86</td></tr></tbody></table>

*** vs. CRP.

<figure><img src="image_9.png" /><figcaption>**Figure 5.** Comparison of ROC curves to support a poor outcome designed for PCO (black circles, continuous line), CRP (black triangles, dotted line) and PON1 (black squares, dashed line). The graph on the left (A) includes the results of the three groups of dogs, the graph on the right (B) includes only the results of dogs with sepsis or trauma. The grey line indicates the line of no discrimination. TPF = true positive fraction; FPF = false positive fraction.</figcaption></figure>

The AUC of PCO and CRP did not significantly differ from the line of no discrimination although the P value of PCO was close to the level of significance (*p* = 0.068). No significant differences were found between the AUCs of PCO and CRP (*p* = 0.218) or of PCO and PON1 (*p* = 0.062). The exclusion of clinically healthy dogs provided the same results: although the AUCs were lower for all the analytes, only the AUC of PON1 was significantly different from the line of no discrimination (*p* < 0.001) and significantly higher than the AUC of CRP (*p* < 0.001). The AUC of PCO and CRP did not significantly differ from the line of no discrimination and were not significantly different to each other (*p* = 0.339) as well as no significant differences were found between the AUCs of PCO and PON1 (*p* = 0.069).

The highest Youden index was found for PON1, although the cut-off to discriminate dead vs. alive dogs was lower when clinically healthy dogs were excluded from the analysis, as expected. The same occurred for PCO and CRP whose optimal cut-offs were higher when clinically healthy dogs are excluded than when clinically healthy dogs are included in the analysis. All the tests had the highest LR+ or absolute specificity at similar
cut-offs, independent of the presence or absence of clinically healthy dogs. However, the LR+ were obviously lower when clinically healthy dogs were excluded and the maximum specificity was detected only at very high values of CRP or PCO or at very low values of PON1.

**4. Discussion**

In several species, it has already been proved that sepsis induces an acute phase reaction, that in turn is characterized by an increase of acute phase proteins such as CRP [18,51,52], and by oxidative phenomena. The latter may induce protein oxidation, leading to the increase of the serum concentration of PCO [40,41] and to the decrease of antioxidant compounds, including the enzyme paraoxonase-1 [33,53,54]. Different studies are available about the utility of CRP to distinguish dogs with sepsis from dogs with sterile inflammation [55-59], but only a recent study demonstrated that PON1 may be useful to discriminate dogs with sepsis from dogs with non-septic inflammation, although ultimately, CRP and albumin may better predict the outcome [60] and no information is available about the utility of PCO in dogs as diagnostic or prognostic marker, differently from human medicine [28,29,32,54,61-63].

In the case where a possible diagnostic or prognostic role could be demonstrated, the evaluation of CRP, PCO and/or PON1 could be recommended as a tool to better focus on the severity of the inflammatory status in the enrolled patients. To this aim, two different approaches have been followed. First, the comparison of results, the evaluation of sensitivity and specificity and the ROC curves analysis was performed by including the whole caseload, composed by both sick and clinically healthy dogs, in order to simulate the use of the markers for screening purposes independently of a pre-test probability of disease. Then, the comparison was performed excluding the control group, to simulate the use of the markers for diagnostic purposes in animals on which a diagnosis of a condition potentially associated with sepsis has already been formulated.

This study confirmed the possible role of CRP in supporting a clinical diagnosis of sepsis, as already evidenced by previous studies [18-20], since, regardless of the inclusion or the exclusion of clinically healthy dogs, the highest concentration of CRP was found in dogs with sepsis and the ROC curve analysis demonstrated that CRP had the highest AUC. However, CRP concentration was increased also in dogs with trauma, that likely had an hyperacute, although non-infectious, inflammation. This confirmed that increases of CRP may occur in different inflammatory conditions and are thus not specific for sepsis [18,21-26] and slightly decreased the diagnostic performance of CRP when the test was applied only on sick dogs. A similar trend was observed for PON1, that was significantly lower in septic dogs than in the other two groups and decreased also in dogs with polytrauma compared with controls. The AUC of the ROC curve referred to PON1, in agreement with what was reported by [60], was slightly lower, but not significantly different from that of CRP, although, also in this case, the diagnostic performance of the test decreased, but remained acceptable, when only sick dogs were considered.

From this perspective and compared with PCO, CRP and PON1 seem to be better markers to differentiate the three conditions considered in this study. This hypothesis is confirmed both by the group comparisons and by the analysis of the ROC curves. Additionally, the LR+ of CRP and, to a lesser extent, of PON1 were notably higher than that of PCO either on the whole caseload or when the tests were applied to discriminate groups of sick dogs. However, the concentration of CRP characterized by absolute specificity was relatively high, and the PON1 activity characterized by absolute specificity was relatively low, compared with the upper and lower limits of the reference interval, respectively. Hence, moderate increases of CRP or moderate decreases of PON1 may not differentiate dogs with sepsis from dogs with non-septic conditions.

Moreover, the comparison of results from dogs that died during the follow up with survivors suggests that the decrease of PON1 and, to a lesser extent, the increase of CRP may predict a poorer outcome. More specifically, the analyte that better differentiated dogs
with a poor outcome in clinical settings on which the likelihood of death is high, was found to be PON1 activity. In fact, the concentration of CRP did not show significant differences between survivors and non-survivors when healthy controls, which are obviously not supposed to die, were excluded from the analysis. Ultimately, when data were examined on the whole caseload, results were in contrast with those of [64], who demonstrated that CRP levels did not differ between survivors and non-survivors, but were in agreement with the study of [65], in which CRP was considered a potentially useful clinical marker for the presence and resolution of systemic inflammation induced by infectious agents in dogs. Our results also agree with those of [60], although these authors reported increased CRP as a better predictor of negative outcome than decreased PON1. These discrepancies may be explained by the different composition of the caseload, especially considering the lack of a uniform consensus regarding the inclusion criteria of septic patients among existing studies. This aspect remains troublesome and partially impairs a fair comparison of biomarkers between patients enrolled with different criteria, as demonstrated by a superior role of PON1 compared with CRP in predicting the outcome after exclusion of clinically healthy dogs. This clinical scenario, however, is much more adherent to what may happen in practice, when prognostic information is needed in dogs with a high pre-test probability of disease. To reduce discrepancies between different studies about sepsis diagnosis and to support the clinical work, further research about diagnostic and prognostic markers of sepsis should indeed be encouraged. In any case, based on the analysis of LR+ and cut-off values characterized by maximum specificity, it should be stressed that either PON1 or CRP may be excellent indicators of a poor prognosis only if recorded values are, respectively, extremely low or high compared with the reference intervals. Independently of all the comments above or of the inclusion/exclusion of clinically healthy dogs, PCO seems not to predict the outcome in dogs.

A limitation of this study is that the presence of oxidation was not confirmed by the measurement of oxidants such as reactive oxygen species, or other indirect reliable markers of oxidation, such as thiobarbituric acid reactive substances or malondialdehyde [66,67]. However, the study was focused on markers that can be easily used in routine practice and that are known to be associated with oxidation. This association is further confirmed by the negative correlation found, as expected, between PCO and PON1. Ultimately, the comparison of results of CRP, PCO and PON1 confirm the hypothesis that in dogs with sepsis, oxidative phenomena are stronger than in dogs with non-septic inflammation, as already demonstrated for people [68–72]. This hypothesis is supported also by the positive correlation between CRP and PCO and by the negative correlation between PCO and the other two markers. However, the magnitude of oxidation seems to affect the kinetic of the two analytes in different ways. More specifically, oxidation of proteins, which is responsible for the increased concentration of PCO, seems to occur in any inflammatory condition able to determine an increase of CRP, including those not associated with infectious agents. On the contrary, the decrease of PON1 activity, which depends on a more complex mechanism involving decreased hepatic production and displacement of circulating PON1 from oxidized lipoproteins [34], seems to occur only when inflammation is more severe, as it usually happens in sepsis. Independent of the possible mechanisms by which oxidation differently affects the two compounds, based on our results, PCO cannot be considered reliable markers to distinguish dogs with sepsis from dogs with non-septic inflammation or predict the outcome, while PON1 and CRP may be considered adequate markers to support a clinical diagnosis of sepsis and provide prognostic information on the possible outcome. A second limitation of the study was the lack of clinical information about severity of disease and organ dysfunction for many dogs. These aspects would have been remarkable to evaluate, but unfortunately, as a retrospective study, the retrieval of such information was frequently troublesome. Finally, another limitation was the lack of repeated sampling during the follow up. This would be particularly important to assess a possible prognostic role of PCO not detected by a single measurement at admission. Fluctuations over time of PCO concentrations may have provided prognostic information, as demonstrated for other
markers with a limited prognostic role at admission, such as calprotectin, procalcitonin, CRP or PON1 [17,36,73–76].

In our opinion, measurement of CRP and PON1 could be an advisable tool to support a clinical diagnosis of sepsis and predict the outcome in routine practice. In clinical practice, the use of CRP as marker of inflammation is already established and widespread, while evaluation of PON1 is to date quite limited to the research field. However, PON1 measurement is quite inexpensive and, given that interest about its applications in veterinary medicine has lately been raised, its measurement may become easily accessible for clinical practice in the future years.

**5. Conclusions**

In conclusion, these results confirm that oxidation is present during inflammatory conditions and especially in sepsis and support the role of CRP and PON1 in confirming a clinical diagnosis of sepsis. Moreover, the measurement of PON1 and CRP at admission, but not of PCO, may predict the possible outcome of dogs with sepsis. Future studies on a larger caseload or on serial measurements of these markers over time may provide additional information about their prognostic role in septic dogs.

**Author Contributions:** Conceptualization, B.R., S.P. and M.G.; methodology, B.R., D.S., S.P.; software—validation, B.R., D.S. and S.P.; investigation, B.R., D.S., R.T., M.G., F.D., and S.P.; resources, B.R., and M.G.; data curation, B.R., D.S., and S.P.; writing—original draft preparation, B.R. and S.P.; writing—review and editing, D.S. and M.G.; supervision, S.P.; project administration, S.P. and M.G.; funding acquisition, S.P., B.R., and D.S. contributed equally to this paper. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Ethical approval was granted by decision n°2/2016 of the Ethical committee of the University of Milan. According to the guidelines of the Institutional Animal Care and Use Committee of the University of Milan, a formal approval was not required, as blood samples were collected for diagnostic purposes or as part of health checks and with in-formed consent of the owners.

**Informed Consent Statement:** Informed consent was obtained from all the owners involved in the study.

**Data Availability Statement:** Data is contained within the article (tables and dot plots).

**Acknowledgments:** The authors thank the colleagues working in the Veterinary Teaching Hospitals for providing the samples and particularly Andrea Colli for its contribution.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Matthiesen, D.T.; Mullen, H.S. Problems and complications associated with endocrine surgery in the dog and cat. *Probl. Vet. Med.* **1990**, *2*, 627–667. [PubMed]

2. Badalov, N.; Baradarian, R.; Iswara, K.; Li, J.; Steinberg, W.; Tenner, S. Drug-induced acute pancreatitis: An evidence-based review. *Clin. Gastroenterol. Hepatol.* **2007**, *5*, 648–661. [CrossRef] [PubMed]

3. Lem, K.; Fosgate, G.; Norby, B.; Steiner, J.M. Associations between dietary factors and pancreatitis in dogs. *J. Am. Vet. Med. Assoc.* **2008**, *233*, 1425–1431. [CrossRef] [PubMed]

4. Xenoulis, P.G.; Suchodolski, S.J.; Ruaux, C.G.; Steiner, J.M. Association between serum triglyceride and canine pancreatic lipase immunoreactivity concentrations in miniature schnauzers. *J. Am. Anim. Hosp. Assoc.* **2010**, *46*, 229–234. [CrossRef]

5. Suchodolski, J.S.; Dowd, S.E.; Westermarck, E.; Steiner, J.M.; Wolcott, R.D.; Spillmann, T.; Harmoinen, J.A. The effect of the macrolide antibiotic tylosin on microbial diversity in the canine small intestine as demonstrated by massive parallel 16S rRNA gene sequencing. *BMC Microbiol.* **2009**, *9*, 210. [CrossRef] [PubMed]

6. Maynard, C.L.; Elson, C.O.; Hatton, R.D.; Weaver, C.T. Reciprocal interactions of the intestinal microbiota and immune system. *Nature* **2012**, *489*, 231–241. [CrossRef]

7. Werner, M.; Suchodolski, J.S.; Straubinger, R.K.; Wolf, G.; Steiner, J.M.; Lidbury, J.A.; Neurer, F.; Hartmann, K.; Unterer, S. Effect of Amoxicillin-Clavulanic acid on clinical scores, intestinal microbiome, and Amoxicillin-resistant Escherichia Coli in dogs with uncomplicated acute diarrhea. *J. Vet. Intern. Med.* **2020**, *34*, 1166–1176. [CrossRef]
8. Soulountsi, V.; Schizodimos, T. Use of antibiotics in acute pancreatitis: Ten major concerns. *Scand. J. Gastroenterol.* **2020**, *1–8*.
[CrossRef]

9. Giunti, M.; Grossi, G.; Troia, R.; Fracassi, F.; Dondi, F. Evaluation of serum apolipoprotein A1 in canine sepsis. *Front. Vet. Sci.* **2020**, *7*, 263. [CrossRef]

10. Torrente, C.; Manzanilla, E.G.; Bosch, L.; Villaverde, C.; Pastor, J.; Ruiz de Gopegui, R.; Tvarijonaviciute, A. Adiponectin as a sepsis biomarker in dogs: Diagnostic and prognostic value. *Vet. Clin. Pathol.* **2020**, *49*, 333–344. [CrossRef] [PubMed]

11. Troia, R.; Ciuffoli, E.; Vasylyeva, K.; Foglia, A.; Dondi, F.; Giunti, M. Circulating methemoglobin fraction in dogs with sepsis. *Front. Vet. Sci.* **2020**, *7*, 341. [CrossRef]

12. Marik, P.E.; Stephenson, E. The ability of procalcitonin, lactate, white blood cell count and neutrophil-lymphocyte count ratio to predict blood stream infection. Analysis of a large database. *J. Crit. Care* **2020**, *60*, 135–139. [CrossRef]

13. Kyriazopoulou, E.; Liaskou-Antoniou, L.; Adamis, G.; Panagaki, A.; Melachroinopoulos, N.; Drakou, E.; Marousis, K.; Chrysos, G.; Spyrou, A.; Alexiou, N.; et al. Procalcitonin to reduce long-term infection-associated adverse events in sepsis: A randomized trial. *Am. J. Respir. Crit. Care Med.* **2021**, *203*, 202–210. [CrossRef] [PubMed]

14. Floras, A.N.K.; Holowaychuk, M.K.; Hodgins, D.C.; Marr, H.S.; Birkenheuer, A.; Sharif, S.; Bersenas, A.M.E.; Bienzle, D. Investigation of a commercial ELISA for the detection of canine procalcitonin. *J. Vet. Intern. Med.* **2014**, *28*, 599–602. [CrossRef] [PubMed]

15. Easley, F.; Holowaychuk, M.K.; Lashnits, E.W.; Nordone, S.K.; Marr, H.; Birkenheuer, A.J. Serum procalcitonin concentrations in dogs with induced endotoxiemia. *J. Vet. Intern. Med.* **2020**, *34*, 653–658. [CrossRef] [PubMed]

16. Goggs, R.; Milloway, M.; Troia, R.; Giunti, M. Plasma procalcitonin concentrations are increased in dogs with sepsis. *Vet. Rec. Open* **2018**, *5*, e000255. [CrossRef]

17. Troia, R.; Giunti, M.; Goggs, R. Plasma procalcitonin concentrations predict organ dysfunction and outcome in dogs with sepsis. *BMC Vet. Res.* **2018**, *14*, 111. [CrossRef]

18. Cerón, J.J.; Eckersall, P.D.; Martínez-Subiela, S. Acute phase proteins in dogs and cats: Current knowledge and future perspectives. *Vet. Clin. Pathol.* **2005**, *34*, 85–99. [CrossRef] [PubMed]

19. Fransson, B.A.; Lagerstedt, A.S.; Bergstrom, A.; Hagman, R.; Park, J.S.; Chew, B.P.; Evans, M.A.; Ragle, C.A. C-Reactive protein, tumor necrosis factor α, and interleukin-6 in dogs with pyometra and SIRS. *J. Vet. Emerg. Crit. Care* **2007**, *17*, 373–381. [CrossRef]

20. Gebhardt, C.; Hirschberger, J.; Rau, S.; Arndt, G.; Krainer, K.; Schweigert, F.J.; Brunnberg, L.; Kaspers, B.; Kohn, B. Use of C-reactive protein to predict outcome in dogs with systemic inflammatory response syndrome or sepsis. *J. Vet. Emerg. Crit. Care* **2009**, *19*, 450–458. [CrossRef] [PubMed]

21. Jergens, A.E.; Schreiner, C.A.; Frank, D.E.; Niyo, Y.; Ahrens, F.E.; Eckersall, P.D.; Benson, T.J.; Evans, R. A scoring index for disease activity in canine inflammatory bowel disease. *J. Vet. Intern. Med.* **2003**, *17*, 291–297. [CrossRef]

22. Tecles, F.; Spiranelli, E.; Bonfanti, U.; Cerón, J.J.; Paltrinieri, S. Preliminary studies of serum acute-phase protein concentrations in hematologic and neoplastic diseases of dog. *J. Vet. Intern. Med.* **2005**, *19*, 965–970. [CrossRef]

23. Raila, J.; Schweigert, F.J.; Kohn, B. C-Reactive protein concentrations in serum of dogs with naturally occurring renal disease. *J. Vet. Diagn. Investig.* **2011**, *23*, 710–715. [CrossRef] [PubMed]

24. Polizopoulou, Z.S.; Koutinas, C.K.; Cerón, J.J.; Tvarijonaviciute, A.; Martínez-Subiela, S.; Dasopoulou, A.; York, M.J.; Roman, F.; Gandhi, M.; Patel, S.; et al. Correlation of serum cardiac troponin I and acute phase protein concentrations with clinical staging in dogs with degenerative mitral valve disease. *Vet. Clin. Pathol.* **2015**, *44*, 397–404. [CrossRef]

25. Fazio, F.; Casella, S.; Giannetto, C.; Giudice, E.; Piccione, G. Characterization of acute phase proteins and oxidative stress response to road transportation in the dog. *Exp. Anim.* **2015**, *64*, 19–24. [CrossRef] [PubMed]

26. Hindenberg, S.; Bauer, N.; Moritz, A. Extremely high canine C-reactive protein concentrations > 100 mg/L—Prevalence, etiology and prognostic significance. *BMC Vet. Res.* **2020**, *16*, 147. [CrossRef]

27. Sies, H. Oxidative stress: A concept in redox biology and medicine. *Redox Biol.* **2015**, *4*, 180–183. [CrossRef] [PubMed]

28. Takeda, K.; Shimada, Y.; Amano, M.; Sakai, T.; Okada, T.; Yoshiya, I. Plasma lipid peroxides and alpha-tocopherol in critically ill patients. *Crit. Care Med.* **1984**, *12*, 957–959. [CrossRef] [PubMed]

29. Goode, H.F.; Cowley, H.C.; Walker, B.E.; Howdle, P.D.; Webster, N.R. Decreased antioxidant status and increased lipid peroxidation in patients with septic shock and secondary organ dysfunction. *Crit. Care Med.* **1995**, *23*, 646–651. [CrossRef] [PubMed]

30. Macdonald, J.; Galley, H.F.; Webster, N.R. Oxidative stress and gene expression in sepsis. *Br. J. Anaesth.* **2003**, *90*, 221–232. [CrossRef]

31. Bosmann, M.; Ward, P. The inflammatory response in sepsis. *Trends Immunol.* **2013**, *34*, 129–136. [CrossRef]

32. Amorim de Oliveira, Y.P.A.; Pontes-de-Carvalho, L.C.; Couto, R.D.; Noronha-Dutra, A.A. Oxidative stress in sepsis. Possible production of free radicals through an erythrocyte-mediated positive feedback mechanism. *Braz. J. Infect. Dis.* **2017**, *21*, 19–26. [CrossRef] [PubMed]

33. Feingold, K.R.; Memon, R.A.; Moser, A.H.; Grunfeld, C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. *Atherosclerosis* **1998**, *139*, 307–315. [CrossRef]

34. Rossi, G.; Giordano, A.; Pezzia, F.; Kjelgaard-Hansen, M.; Paltrinieri, S. Serum paraoxonase 1 activity in dogs: Preanalytical and analytical factors and correlation with C-reactive protein and alpha-2-globulin. *Vet. Clin. Pathol.* **2013**, *42*, 329–341. [CrossRef] [PubMed]
35. Carretón, E.; Cerón, J.J.; Martínez-Subiela, S.; Tvarijonaviciute, A.; Caro-Vadillo, A.; Montoya-Alonso, J.A. Acute phase proteins and markers of oxidative stress to assess the severity of the pulmonary hypertension in heartworm-infected dogs. *Parasit. Vectors* **2017**, *10* (Suppl. 2), 477. [CrossRef]

36. Ibba, F.; Rossi, G.; Meazzi, S.; Giordano, A.; Paltrinieri, S. Serum concentration of high density lipoproteins (HDLs) in leishmaniotic dogs. *Res. Vet. Sci.* **2015**, *98*, 89–91. [CrossRef]

37. Rossi, G.; Kuleš, J.; Barić Rafaj, R.; Mriljak, V.; Lauzi, S.; Giordano, A.; Paltrinieri, S. Relationship between paraoxonase 1 activity and high density lipoprotein concentration during naturally occurring babesiosis in dogs. *Res. Vet. Sci.* **2014**, *97*, 318–324. [CrossRef] [PubMed]

38. Daza González, M.A.; Fragío Arnold, C.; Fermín Rodríguez, M.; Checa, R.; Montoya, A.; Portero Fuentes, M.; Rupérez Noguer, C.; Martínez Subiela, S.; Cerón, J.J.; Mirò, G. Effect of two treatments on changes in serum acute phase protein concentrations in dogs with clinical leishmaniosis. *Vet. J.* **2019**, *245*, 22–28. [CrossRef]

39. Dalle-Donne, I.; Rossi, R.; Giustarini, D.; Milzani, A.; Colombo, R. Protein carbonyl groups as biomarkers of oxidative stress. *Clin. Chim. Acta* **2003**, *329*, 23–38. [CrossRef]

40. Dalle-Donne, I.; Scaloni, A.; Giustarini, D.; Cavarra, E.; Tell, G.; Lungarella, G.; Colombo, R.; Rossi, R.; Milzani, A. Proteins as biological markers of oxidative/nitrosative stress in diseases. The contribution of redox-proteomics. *Mass Spectrom. Rev.* **2005**, *24*, 55–99. [CrossRef]

41. Abu-Zidan, F.M.; Plank, L.D.; Windsor, J.A. Proteolysis in severe sepsis is related to oxidation of plasma protein. *Eur. J. Surg.* **2002**, *168*, 119–123. [CrossRef]

42. Ruggerone, B.; Colombo, G.; Paltrinieri, S. Identification of Protein Carbonyls (PCOs) in canine serum by Western Blot Technique and preliminary evaluation of PCO concentration in dogs with systemic inflammation. *Front. Vet. Sci.* **2020**, *7*, 566402. [CrossRef] [PubMed]

43. Vannucchi, C.I.; Jordao, A.A.; Vannucchi, H. Antioxidant compounds and oxidative stress in female dogs during pregnancy. *Res. Vet. Sci.* **2007**, *83*, 188–193. [CrossRef]

44. Escobar, T.A.; Dowich, G.; Pacheco dos Santos, T.; Zuravski, L.; Duarte, C.A.; Lübeck, I.; Manfredini, V. Assessment of Leishmania infantum infection in equine populations in a canine visceral leishmaniosis transmission area. *BMC Vet. Res.* **2019**, *15*, 381. [CrossRef]

45. Zini, E.; Gabbai, G.; Salesov, E.; Gerardi, G.; Da Dalt, L.; Lutz, T.A.; Reusch, C. Oxidative status of erythrocytes, hyperglycemia, and hyperlipidemia in diabetic cats. *J. Vet. Intern. Med.* **2020**, *34*, 616–625. [CrossRef]

46. Hauptman, J.G.; Walshaw, R.; Olivier, N.B. Evaluation of the sensitivity and specificity of diagnostic criteria for sepsis in dogs. *Vet. Surg.* **1997**, *26*, 393–397. [CrossRef]

47. Rossi, G.; Ibba, F.; Meazzi, S.; Giordano, A.; Paltrinieri, S. Paraoxonase activity as a tool for clinical monitoring of dogs treated for canine leishmaniasis. *Vet. J.* **2014**, *199*, 143–149. [CrossRef] [PubMed]

48. Gardner, I.A.; Greiner, M. Receiver-operating characteristic curves and likelihood ratios: Improvements over traditional methods for the evaluation and application of veterinary clinical pathology tests. *Vet. Clin. Pathol.* **2006**, *35*, 8–17. [CrossRef] [PubMed]

49. Christenson, R.H. Evidence-based laboratory medicine—A guide for critical evaluation of in vitro laboratory testing. *Ann. Clin. Biochem.* **2007**, *44*, 1367–1371. [CrossRef] [PubMed]

50. Ruopp, M.D.; Perkins, N.J.; Whitcomb, B.W.; Schisterman, E.F. Youden Index and optimal cut-point estimated from observations affected by a lower limit of detection. *Biom. J.* **2008**, *50*, 419–430. [CrossRef]

51. Cray, C.; Zaias, J.; Altman, N.H. Acute phase response in animals: A review. *Comp. Med.* **2009**, *59*, 517–526.

52. Tothova, C.; Nagy, O.; Kovac, G. Serum proteins and their diagnostic utility in veterinary medicine: A review. *Vet. Med.* **2016**, *61*, 475–496. [CrossRef]

53. Cabana, V.G.; Reardon, C.A.; Feng, N.; Neath, S.; Lukens, J.; Getz, G.S. Serum paraoxonase: Effect of the apolipoprotein composition of HDL and the acute phase response. *J. Lipid Res.* **2003**, *44*, 780–792. [CrossRef] [PubMed]

54. Novak, F.; Vavrova, L.; Kodydkova, J.; Novak Sr, F.; Hynkova, M.; Zak, A.; Novakova, O. Decreased paraoxonase activity in critically ill patients with sepsis. *Clin. Exp. Med.* **2010**, *10*, 21–25. [CrossRef] [PubMed]

55. Yamamoto, S.; Shida, T.; Okimura, T.; Otabe, K.; Honda, M.; Ashida, Y.; Furukawa, E.; Sarikaputi, M.; Naiki, M. Determination of C-reactive protein in serum and plasma from healthy dogs and dogs with pneumonia by ELISA and slide reversed passive latex agglutination test. *Vet. Quart.* **1994**, *16*, 74–77. [CrossRef] [PubMed]

56. Martínez-Subiela, S.; Tecles, F.; Eckersall, P.D.; Cerón, J.J. Serum concentrations of acute phase proteins in dogs with leishmaniasis. *Vet. Rec.* **2002**, *150*, 241–244. [CrossRef]

57. Fransson, B.A.; Karlstam, E.; Bergstrom, A.; Lagerstedt, A.S.; Park, J.S.; Evans, M.A.; Ragle, C.A. C-reactive protein in the differentiation of pyometra from cystic endometrial hyperplasia/mucometra in dogs. *J. Am. Anim. Hosp. Assoc.* **2004**, *40*, 391–399. [CrossRef]

58. Jitpean, S.; Holst, B.S.; Hoglund, O.V.; Petterson, A.; Olsson, U.; Strage, E.; Södersten, F.; Hagman, R. Serum insulin-like growth factor-1, iron, C-reactive protein, and Serum Amyloid A for prediction of outcome in dogs with pyometra. *Theriogenology* **2014**, *82*, 43–48. [CrossRef]

59. Viitanen, S.J.; Laurilla, H.P.; Lilija-Maula, L.I. Serum C-reactive protein as a diagnostic biomarker in dogs with bacterial respiratory diseases. *J. Vet. Intern. Med.* **2014**, *28*, 84–91. [CrossRef]
60. Torrente, C.; Manzanilla, E.G.; Bosch, L.; Villaverde, C.; Pastor, J.; de Gopegui, R.R.; Tvarijonaviciute, A. The diagnostic and prognostic value of paraoxonase-1 and butyrylcholinesterase activities compared with acute-phase proteins in septic dogs and stratified by the acute patient physiologic and laboratory evaluation score. *Vet. Clin. Pathol.* **2019**, *48*, 740–747. [CrossRef] [PubMed]

61. Bavunoglu, I.; Genc, H.; Konukoglu, D.; Cicecki, H.; Sozer, V.; Gelisgen, R.; Uzun, H. Oxidative stress parameters and inflammatory and immune mediators as markers of the severity of sepsis. *J. Infect. Dev. Ctries* **2016**, *10*, 1045–1052. [CrossRef]

62. Camps, J.; Iftimie, S.; García-Heredia, A.; Castro, A.; Joven, J. Paraoxonases and infectious diseases. *Clin. Biochem.* **2017**, *50*, 804–811. [CrossRef]

63. Bednarz-Misa, I.; Mierzchala-Pasierb, M.; Lesnik, P.; Placzkowska, S.; Kedzior, K.; Gamina, A.; Krystek-Korpacka, M. Cardiovascular insufficiency, abdominal sepsis, and patients' age are associated with decreased paraoxonase-1 (PON-1) activity in critically ill patients with multiple organ dysfunction syndrome (MODS). *Dis. Markers* **2019**, *2019*, 1314623. [CrossRef]

64. Meisner, M.; Adina, H.; Schmidt, J. Correlation of procalcitonin and C-reactive protein to inflammation, complications, and outcome during the intensive care unit course of multiple-trauma patients. *Crit. Care* **2006**, *10*, R1. [CrossRef] [PubMed]

65. Kjelgaard-Hansen, M.; Kristensen, A.T.; Jensen, A.L. Evaluation of a commercially available enzyme-linked immunosorbent assay (ELISA) for the determination of C-reactive protein in canine serum. *J. Vet. Med. A Physiol. Pathol. Clin. Med.* **2003**, *50*, 164–168. [CrossRef]

66. Da Silva, A.S.; Munhoz, T.D.; Faria, J.L.; Vargas-Hérnandez, G.; Machado, R.Z.; Almeida, T.C.; Moresco, R.N.; Stefani, L.M.; Tinucci-Costa, M. Increase nitric oxide and oxidative stress in dogs experimentally infected by Ehrlichia canis: Effect on the pathogenesis of the disease. *Vet. Microbiol.* **2013**, *164*, 366–369. [CrossRef]

67. Bottari, N.B.; Munhoz, T.D.; Torbitz, V.D.; Tonin, A.A.; Anai, L.A.; Semolin, L.M.S.; Jark, P.C.; Bollicj, Y.S.; Moresco, R.N.; França, R.T.; et al. Oxidative stress in dogs with multicentric lymphoma: Effect of chemotherapy on oxidative and antioxidant biomarkers. *Redox Rep.* **2015**, *20*, 267–274. [CrossRef] [PubMed]

68. Póvoa, P. Serum markers in community-acquired pneumonia and ventilator-associated pneumonia. *Curr. Opin. Infect. Dis.* **2008**, *21*, 157–162. [CrossRef]

69. Lisboa, T.; Seligman, R.; Diaz, E.; Rodriguez, A.; Teixera, P.J.; Rello, J. C-reactive protein correlates with bacterial load and appropriate antibiotic therapy in suspected ventilator-associated pneumonia. *Crit. Care Med.* **2008**, *36*, 166–171. [CrossRef]

70. Cals, J.W.; Butler, C.C.; Hopstaken, R.M.; Hook, K.; Dinant, G.J. Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: Cluster randomized trial. *BMJ* **2009**, *338*, b1374. [CrossRef]

71. Póvoa, P.; Teixera-Pinto, A.M.; Carneiro, A.H.; Portuguese Community-Acquired Sepsis Study Group SACIUCI. C-reactive protein, an early biomarker of community-acquired sepsis resolution: A multi-center prospective observational study. *Crit. Care* **2011**, *15*, R169. [CrossRef] [PubMed]

72. Teggert, A.; Datta, H.; Ali, Z. Biomarkers for Point-of-Care Diagnosis of Sepsis. *Micromachines* **2020**, *11*, 286. [CrossRef]

73. Nielsen, L.; Toft, N.; Eckersall, P.D.; Mellor, D.J.; Morris, J.S. Serum C-reactive protein concentration as an indicator of remission status in dogs with multicentric lymphoma. *J. Vet. Intern. Med.* **2007**, *21*, 1231–1236. [CrossRef] [PubMed]

74. Alexandrakis, I.; Tuli, R.; Ractliffe, S.C.; Tappin, S.W.; Foale, R.D.; Roos, A.; Slater, K.J. Utility of a multiple serum biomarker test to monitor remission status and relapse in dogs with lymphoma undergoing treatment with chemotherapy. *Vet. Comp. Oncol.* **2017**, *15*, 6–17. [CrossRef]

75. Kanno, N.; Hayakawa, N.; Suzuki, S.; Harada, Y.; Yogo, T.; Hara, Y. Changes in canine C-reactive protein levels following orthopaedic surgery: A prospective study. *Acta Vet. Scand.* **2019**, *61*, 33. [CrossRef] [PubMed]

76. Thames, B.E.; Barr, J.W.; Suchodolski, J.S.; Steiner, S.M.; Heilmann, R.M. Prospective evaluation of S100A12 and S100A8/A9 (calprotectin) in dogs with sepsis or the systemic inflammatory response syndrome. *J. Vet. Diagn. Investig.* **2019**, *31*, 645–651. [CrossRef] [PubMed]